Training activity information
Details
Select, perform and interpret tests for bacterial and fungal causes of central nervous system infection using the following techniques and suggest options for management:
- Microscopy and cell count
- Culture, identification and antimicrobial susceptibility testing
- Antigen/antibody detection, eg, pneumococcus, cryptococcus and syphilis
Type
Developmental training activity (DTA)
Evidence requirements
Evidence the activity has been undertaken by the trainee.
Reflection on the activity at one or more time points after the event including learning from the activity and/or areas of the trainees practice for development.
An action plan to implement learning and/or to address skills or knowledge gaps identified.
Reflective practice guidance
The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.
Before action
- Why is the rapid and accurate diagnosis of central nervous system (CNS) infections critical?
- What are the common bacterial and fungal pathogens associated with CNS infections (e.g., meningitis, encephalitis)?
- What is your understanding of microscopy and cell count on cerebrospinal fluid (CSF), culture, identification, antimicrobial susceptibility testing, and antigen/antibody detection (e.g., pneumococcus, cryptococcus, syphilis) in this context?
- What specific skills in performing and interpreting CSF microscopy and cell counts do you hope to develop?
- How will you learn about the interpretation of antigen/antibody detection tests in the CSF?
- What insights do you expect to gain regarding the selection of appropriate empirical and targeted antimicrobial therapy for CNS infections?
- How will you prepare for this DTA?
- Will you review the laboratory protocols for handling and processing CSF samples?
- Will you discuss with your training officer the critical values for CSF cell counts and their significance?
- What challenges might you face in interpreting CSF results in partially treated meningitis?
- How will you approach interpreting serological tests for CNS infections, considering the blood-brain barrier?
- How do you feel about the critical role of the laboratory in diagnosing these potentially devastating infections?
In action
- What specific bacterial and fungal central nervous system (CNS) infection tests are you currently performing or interpreting (e.g., CSF Gram stain and cell count, bacterial and fungal culture of CSF, latex agglutination for cryptococcal antigen, syphilis serology on CSF)?
- How are you approaching the execution or interpretation of these assays? Why are you doing it this way (e.g., understanding the significance of CSF cell counts and protein levels, using specialised culture media for CNS pathogens)?
- What decisions are you making regarding the interpretation of discordant results between different tests?
- What aspects of performing or interpreting these tests feel intuitive to you, and what requires more conscious effort (e.g., recognising subtle bacterial morphology in CSF, interpreting low-positive antigen tests)?
- How effective are your current actions in obtaining or interpreting clinically relevant results for CNS infections?
- What challenges are you facing during the process (e.g., low yield from CSF cultures, interpreting the significance of a positive syphilis serology in CSF)?
- What can you learn about diagnosing CNS infections and the critical nature of rapid and accurate results as the activity unfolds?
- How does this activity connect to your understanding of meningitis, encephalitis, and other CNS infections?
- Are there alternative approaches you could be considering if initial tests are inconclusive (e.g., requesting molecular tests for specific CNS pathogens, repeating lumbar puncture)?
- What support or guidance might you need in this moment from a senior colleague or the training officer regarding the interpretation of complex CSF findings?
- Are you working within your scope of practice when selecting, performing, and interpreting these tests and considering management options?
On action
- Begin by summarising the key points of the experience working with CNS samples (like CSF) for bacterial and fungal investigations.
- What were the most significant observations regarding sample handling, techniques (Microscopy/cell count, Culture, AST, Antigen/antibody detection), or the urgency of processing these samples?
- What skills or knowledge did you develop or improve through this DTA, specifically in performing microscopy and cell counts on CSF, culturing CNS pathogens, performing AST, using antigen/antibody detection tests (e.g., for Pneumococcus, Cryptococcus, syphilis), interpreting integrated findings, or suggesting management?
- Were there any unexpected challenges (e.g., low cell counts, difficult to culture organisms, interpreting antigen tests) or successes?
- What did you learn from these? In what ways did your ‘reflection-in-action’ influence your approach during the activity, such as prioritising microscopy or deciding on the most appropriate antigen test?
- What areas for continued development have been identified, perhaps concerning accurate cell counts in CSF, recognising rare pathogens on microscopy, or interpreting antigen detection results in context?
- How can you apply the learning from this activity to your routine practice when processing and reporting CNS samples?
- Identify the specific actions or ‘next steps’ you will take to consolidate this learning. What support or resources might you need to further develop in these areas?
Beyond action
- Revisit your initial reflect-on-action notes for this DTA. What additional insights have you gained since the initial reflection?
- Has discussing critical CNS infection cases at MDT meetings or with clinicians altered your perspective on the urgency and interpretation of results?
- How did this specific CNS testing experience compare to testing from other sterile sites?
- What unique challenges (e.g., managing small volume samples, performing cell counts, interpreting rapid tests) have you identified with CSF samples?
- Have you discussed CNS infection diagnostics or management during professional storytelling with peers or senior colleagues? What new perspectives did this bring regarding rapid diagnostics or specific pathogens?
- How have the skills (e.g., handling critical, small-volume samples, performing manual cell counts and microscopy accurately, interpreting rapid antigen tests, understanding the clinical significance of findings) you developed during this DTA influenced your approach to other critical samples?
- Have you applied the learning from this DTA, such as recognising the critical importance of speed and accuracy or liaising closely with clinical teams, to other aspects of your microbiology practice?
- How does the learning from this DTA contribute to your preparedness for observed assessments like performing a manual cell count and Gram stain of a CSF sample?
- What transferable skills in managing critical samples under extreme time pressure, applying a range of rapid and standard techniques, interpreting results in life-threatening situations, and communicating urgent findings effectively, developed through this DTA, will be invaluable throughout your training and beyond?
- Identify clear actions for continued development related to CNS diagnostics, rapid testing, or critical result reporting based on your cumulative experiences and reflections.
Relevant learning outcomes
| # | Outcome |
|---|---|
| # 1 |
Outcome
Select and perform tests to investigate common infections from a range of sample types following guidance and fulfilling health and safety requirements |
| # 2 |
Outcome
Interpret the results of tests used to investigate common infections from a range of sample types with consideration of laboratory quality assurance and quality control |
| # 3 |
Outcome
Identify options for management of common infections based on test results and clinical context, considering infection control, guidelines and public health requirements |